Everpar Advisors LLC Has $262,000 Stock Position in Zoetis Inc. $ZTS

Everpar Advisors LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 11.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,677 shares of the company’s stock after purchasing an additional 174 shares during the period. Everpar Advisors LLC’s holdings in Zoetis were worth $262,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Webster Bank N. A. boosted its holdings in shares of Zoetis by 25.3% in the second quarter. Webster Bank N. A. now owns 554 shares of the company’s stock worth $86,000 after buying an additional 112 shares during the period. NBC Securities Inc. boosted its holdings in shares of Zoetis by 2.1% in the second quarter. NBC Securities Inc. now owns 13,179 shares of the company’s stock worth $2,055,000 after buying an additional 271 shares during the period. Quintet Private Bank Europe S.A. boosted its holdings in shares of Zoetis by 2.5% in the second quarter. Quintet Private Bank Europe S.A. now owns 4,954 shares of the company’s stock worth $773,000 after buying an additional 120 shares during the period. Trust Co. of Oklahoma boosted its holdings in shares of Zoetis by 2.7% in the second quarter. Trust Co. of Oklahoma now owns 7,101 shares of the company’s stock worth $1,107,000 after buying an additional 190 shares during the period. Finally, Value Partners Investments Inc. boosted its holdings in shares of Zoetis by 7.2% in the second quarter. Value Partners Investments Inc. now owns 14,367 shares of the company’s stock worth $2,237,000 after buying an additional 959 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on ZTS shares. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Trading Up 0.8%

NYSE:ZTS opened at $147.44 on Wednesday. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The firm has a market cap of $65.34 billion, a price-to-earnings ratio of 25.38, a P/E/G ratio of 2.35 and a beta of 0.89. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company’s 50 day moving average is $151.90 and its 200-day moving average is $156.99.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.